Prime Medicine (NASDAQ:PRME) Shares Down 3.7% Following Analyst Downgrade

Key Points

• Prime Medicine shares fell by 3.7% following a downgrade from a hold to a sell rating by Wall Street Zen.
• The company's stock traded as low as $3.09 during the session, with an average trading volume decline of 4%.
• Prime Medicine, with a market cap of $419.86 million, focuses on delivering one-time curative genetic therapies through its Prime Editing technology.

Prime Medicine, Inc. (NASDAQ:PRME - ) traded down 3.7% during trading on Tuesday after Wall Street Zen downgraded the stock from a hold rating to a sell rating. The company traded as low as $3.09 and last traded at $3.12. 3,103,838 shares were traded during mid-day trading, a decline of 4% from the average session volume of 3,243,728 shares. The stock had previously closed at $3.24.

Prime Medicine Stock Down 3.7%

The firm has a market cap of $419.86 million, a PE ratio of -2.00 and a beta of 2.38.

Prime Medicine Company Profile

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.